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Abstract: The discovery of the high-affinity, high-specificity folate receptor in mamalian kidney cells, coupled
with the ability of folate to enter cells by folate receptor-mediated endocytosis and the subsequent elucidation of the
folate receptor’s overexpression in specific cancer cell types; heralded the arrival of the area of chemotherapeutic
folate targeting. The application of purely organic folate-based small-molecule drug conjugates that selectively target
the folate receptor, which is over expressed in several diseases such as cancer, is well established. The application of
inorganic folate-targeted drugs offers significant potential to expand and enhance this therapeutic approach. From the
data made available to date, it is apparent that this aspect of inorganic medicinal chemistry is in its youth but has the
capability to contribute greatly to cancer research, both in therapy and diagnosis. The union of folate-receptor targeting
and inorganic medicine may also lead to the development of treatments for disorders such as chronic-inflammation,
tuberculosis, neurodegenerative disease and leishmaniasis. In this review, we summarize what is known about the
coordination chemistry of folic acid and the therapeutic potential of such complexes. We also describe approaches
adopted to conjugate platinum drugs to folate- or folate-carrier- systems and their prospective ability to overcome
problems associated with unwanted side-effects and resistance by improving their delivery and/or selectivity. The
literature pertaining to non-platinum metal complex conjugates with folic acid is also reviewed revealing that this is
an area that offers significant potential to develop targeted therapeutic approaches in areas such as chemotherapy and
molecular imaging for diagnostics.

Keywords: metal-folate complexes, folate receptor-targeted drug delivery, chemotherapeutics, diagnostics.
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1. INTRODUCTION
The origins of folate receptor-targeted chemotherapy can be traced back to 1947; that year Sidney Farber
building upon earlier observations made by Louis S Goodman and Alfred Gilman on the effects of alkylating agents
(mustine) on white blood cells and lymph nodes demonstrated that 4-aminopteroyl-glutamic acid (aminopterin), a
synthetic derivative of the B-vitamin folic acid, resulted in remissions in children with acute leukemia.[1-5]
Aminopterin functions by competing with folate for the binding site of the dihydrofolate reductase (DHFR) enzyme
hence blocking the uptake of folic acid and consequently arresting DNA replication.[6-8] Aminopterin was later
superseded with the advent of methotrexate, an antifolate drug still widely used today, the first drug shown to cure a
metastatic tumor of choriocarcinoma.[9] The success of these initial chemotherapeutics encouraged chemists to seek
new molecules that could inhibit cell replication entirely - The era of cancer chemotherapy had begun.

The paragon of chemotherapy is the “targeting” or site-specific recognition of cancerous tissue by a
therapeutic agent, the proposed ability of such an agent to discern and bind to a unique aspect of cancerous tissue and
then preferentially deliver a precise cytotoxic effect, is a highly desirable attribute. Many examples of the effective
use of this strategy can be found in the literature, including targeted therapies in advanced stages of development and
a small number in clinical use.[10-14] Each type of the proposed targeted chemotherapy utilises a specific molecular
target and the area can be broadly subcategorised into those which employ either cell-surface carbohydrates
(carbohydrate targeting), cellular antigens for antibodies (antibody targeting) or cell surface receptors (receptor
targeting).[15] There are numerous folate receptor targeted therapies currently in various stages of development.
Vintafolide is one such folate receptor targeted therapy, it is a small molecule drug conjugate (SMDC), development
of which was halted in Phase III due to poor efficacy on the pre-specified outcome of Progression-Free Survival
(PFS).[16, 17] Other examples of folate receptor targeted therapies in development are the monoclonal antibody
farletuzumab, and the antibody-drug conjugate IMGN853.[18-21]
Given the numerous targeted therapeutic methodologies currently under development, this review will focus
specifically on those utilizing the folate moiety to selectivity target the folate receptor (FR) which is over expressed
on many malignant cell types.[22-33] Furthermore, activated macrophages, also exhibit highly elevated FR
expression; this may also provide a means of preferential targeting of Mycobacterium-infected macrophages and
activated macrophages in inflammatory and autoimmune diseases (rheumatoid, inflammatory and osteoarthritis),
whilst folate targeted conjugates may also hold promise as antileishmanial agents.[34-50]
1.1. Folic acid: structure, function and its role in disease progression
Folic acid (FA) is a member of the family of B9 vitamins, its molecular structure can be subdivided into three
components which consist of a pteridine moiety with A and B rings, linked by a methylene bridge at carbon 6 to paraaminobenzoic acid (PABA), with an amide bond to a glutamic acid moiety (Fig. 1).[51]
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Fig. 1. The structure of folic acid highlighting the three central components; the pteridine ring, para-aminobenzoic
acid (PABA) and the glutamate moiety, atom number also shown for reference. Structure of aminopterin the first
synthetic antifolate agent and methotrexate (MTX) a chemotherapeutic agent developed in 1948 and still in clinical
use today.
The terms ‘folate’ and folic acid are often used interchangeably but it should be noted that folic acid as
depicted in Figure 1 is a pharmacological agent and does not occur in nature.[51] ‘Folate’ is a generic term used to
refer to a number of members of the B9 vitamin family.[52] For the purposes of this review we will refer to folate
(i.e. the deprotonated form of folic acid) and folic acid interchangeably unless otherwise stated. Folic acid is the form
used in vitamin supplement tablets and in cell culture media due to its chemical stability, but within cells it is first
reduced to dihydrofolate (DHF) and then to tetrahydrofolate (THF) (Fig. 2).[51]
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Fig. 2. Folic acid is reduced to dihydrofolic acid (DFA), which is in turn reduced to tetrahydrofolic acid (TFA) in
reactions catalysed by dihydrofolate reductase (DHFR). 5-Methyltetrahydrofolic acid (5-methylTHF) is the major
folate found in blood.[51]
Endogenous folic acid is not found in human cells and is derived entirely from dietary sources with 5methyltetrahydrofolic acid (5-methylTHF) (Fig. 2) being the major folate derived from dietary sources and the
dominant folate found in the blood of humans and rodents.[51]
In 1948, antifolate agents such as aminopterin (Fig. 1) were found to be the first agents to induce temporary
remission when administered to children with acute lymphoblastic leukemia.[3] In later years others demonstrated
that the use of methotrexate (MTX) against solid tumors which were much more effective than in leukemia, achieving
complete remission in breast cancer, choriocarcinoma, chorioadenoma and mycosis fungoides a form of cutaneous Tcell lymphoma.[9, 53-55] MTX supplanted aminopterin in the clinic during the 1950s due to its reported superior
therapeutic index, although this apparent superior therapeutic capability of MTX over that of aminopterin has recently
become the subject of further investigation [56-60] As is clearly evident in Figure 1, folic acid, aminopterin and MTX
are structurally similar, with aminopterin differing from folic acid only in the substitution of an amino for a hydroxyl
group at the N4-position of the pteridine ring. MTX in comparison to aminopterin possess an addition methyl group
at the N10 position, in the bridge between the pteridine and p-amino-benzoic acid moieties.[61] Initially little was
known about the biochemical and molecular pharmacology of MTX and its exact mode of action which hampered
efforts to synthesise new structurally related antifolate derivatives.[62] Pemetrexed, the second antifolate, was
approved in 2004 more than fifty years after MTX and is an effective treatment for malignant pleural mesothelioma
and non-small cell lung cancer.[63-66] In addition, a new generation of antifolates or folate antimetabolites are under
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investigation or in clinical use, some of which are dihydrofolate reductase (DHFR) inhibitors such as Talotrexin which
has a higher binding affinity for DHFR than MTX and other examples such as Raltitrexed, Lometrexol and ONX0801
(Phase 1 trials) inhibit other crucial enzymes in the folate metabolism pathway.[58, 67-72]

1.2. Folate uptake into cells and tissues
The cellular uptake of folate is mediated by three distinct transporters; the reduced folate carrier (RFC),
proton coupled folate transporter (PCFT) and the folate receptor (FR). A review by Zhao et al details the structure and
function of the RFC and the PCFT.[73] The RFC, is the predominant folate transporter expressed in normal adult
tissue and is ubiquitously expressed in the intestine, hepatocytes, choroid plexus and renal epithelial cells, in addition
it facilitates transplacental transport of folates and folate transport across the blood-brain barrier.[74-77] It is a
transmembrane anion exchanger with a Km for 5-methylTHF, 5-formylTHF in the range of 3-7 µM and a very low
affinity for folic acid (Ki approx. 150-200 µM).[73] The PCFT is the main transporter of folate in lower pH
environments, such as the intestine.[78]
The folate receptor (FR) is a glycopolypeptide with high affinity for binding and transporting physiological
concentrations of folate into cells. The human FR family comprises of four isoforms –α, -β, -γ and -δ. Of the four,
only FRα and FRβ are glycosylphosphatidylinositol (GPI)-linked, or membrane bound proteins while the third, FRγ
is a constitutively expressed secretory protein. The fourth isoform, FRδ, has been identified only from genome
database mining but tissue expression and functionality have not been determined.[79] FRα is a cysteine rich GPIlinked membrane protein which is expressed at high levels in various epithelial cancers of the mammary gland, ovary,
prostate, brain, nose and throat.[80, 81] It exhibits a high affinity (Kd < 10-9 M) for folic acid, a binding affinity ~10
times greater than any other reduced form of the vitamin or the anti-folate drug, methotrexate.[33] Furthermore, it has
been reported that in epithelial ovarian cancer, the histological grade and stage of tumour progression correlates
strongly with FRα expression and consequently that FRα expression is associated with parameters of biological
aggressiveness in ovarian cancers.[82, 83] The expression of the FR-α may also hold potential as both a therapeutic
and prognostic target in a number of different cancers, especially ovarian, colorectal and breast cancer.[27, 84, 85]
High level expression of FRα is significantly associated with triple negative/basal tumors and a correlation has been
found between intense overexpression of FR α and poor prognosis in patients presenting with triple negative breast
cancer.[27] In instances of lung cancer which is the leading cause of cancer death worldwide, Non-small-cell lung
cancer (NSCLC) accounts for 80% of lung cancers and has been shown to express FRα to a high extent.[29, 86, 87]
The physiological process by which both dietary folate and folate-drug conjugates enter FR+ cells is known
as endocytosis. It involves the binding of an exogenous folate-drug conjugate to membrane bound FRs and the
immediate invagination of the plasma membrane around the receptor-ligand complex to form an intracellular vesicle
or endosome. This vesicle acidifies to ~pH 5 through the action of proton pumps, inducing a conformational change

6

Medicinal inorganic folate receptor-targeted compounds

in the receptor and the release of the active drug from the folate delivery system (Fig. 3).[88] However, the precise
pathway(s) have not yet been elucidated and are still widely discussed.[89-92] The work of Wibowo et al strongly
suggested that the pH of the environment plays a major role in the structural rearrangement of the FR, with the folate
binding cleft being in an open conformation at neutral pH and blocked at the acidic pH of the endosome.[93] Receptormediated endocytosis offers an advantage as it is non-destructive to the folate-drug conjugate and, as the folate
receptor is known to recycle regularly between the cytosol and cell surface, an increased drug concentration can be
obtained within the cell.[78, 94] Given the restricted expression of FR isoforms (particularly FRα) on malignant tissue,
in addition to its high affinity for folic acid, folate-mediated drug delivery is clearly advantageous to overcoming
unwanted drug toxicity as well as offering the benefit of increased drug concentration in target cells.

Fig. 3. Folate receptor-mediated endocytosis of folate-drug conjugates. The folate-drug conjugate is taken up into
cells by binding of folate to the folate receptor. Invagination of the plasma membrane results in receptor mediated
endocytosis. The acidic pH (~5) results in dissociation of the drug cargo and the folate receptor is recycled to the cell
surface once more (modified from Leamon et al).[88] RFC: reduced folate carrier.
The application of FR-targeted molecules is not new; there have been many articles and papers published
regarding the conjugation of folates to known organic drug molecules such as taxol, paclitaxel and doxorubicin to
improve drug targeting.[95-97] In addition, the application of folates conjugated to fluorescent molecules as
luminescent probes to detect FR+ tumours is well established due to folic acid’s dual targeting and fluorescent
properties.[98] The advantageous chemotherapeutic potential of folate-targeted inorganic nanoparticles such as
mesoporous

materials,[99-103]

gold-nanoshells,[104-107]

quantum

dots

(QD),[108-111]

and

magnetic
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nanoparticles,[112-118] has also been established. Along with these the applications of other folate-targeted
nanomaterials including liposomes, micelles, dendrimers, oligonucleotides and carbon nanotubes (CNT), which do
not possess metal complexes as the active component, have been reviewed in detail elsewhere.[12, 15, 29, 69]
However, there is a void in the literature regarding the coordination chemistry of folic acid and the conjugation of
folic acid to metal based molecules and even less regarding their chemotherapeutic capabilities. A review of the
literature returned fewer than thirty relevant articles concerning metal-folate complexes, many of which focus on the
synthesis and characterisation of metal-folate complexes but do not further investigate any mechanism of action. The
main focus of this review article is the targeted uptake of folate-containing metal complexes or folate-metal complex
conjugates via the FR. FR targeting molecular conjugates or small molecule drug conjugates (SMDC) of a purely
organic chemical structure will not be discussed in detail but will be referenced where necessary.

2. FOLATE TARGETED CHEMOTHERAPY
In 1986, Kamen et al, a group from the University of Texas Southwestern Medical Centre reported that
monkey kidney cells (MA104) possess a high-affinity, high-specificity folate receptor whose expression is regulated
by the folate content of the cell and suggested that a small molecule such as folate can enter cells by receptor-mediated
endocytosis.[119] In the early 1990’s Leamon and Low t showed that like the free vitamin, proteins conjugated to
folic acid could enter certain cells by high affinity receptor mediated endocytosis with the covalent attachment to
folate and forming a folate conjugate, virtually any size macromolecule could be capable of entering the cytoplasm of
the folate receptor (FR) bearing cells in an intact state.[120-122]
These discoveries led to the development of the area of chemotherapeutic folate targeting. These covalent
folate conjugates can be thought of as “molecular Trojan horses” which can leverage the high affinity/specificity of
folate towards the folate receptor.[122] The FR has a low level of expression in healthy tissue but is expressed at high
levels in many cancers (breast, ovarian, brain, prostate etc.) in order to meet the folate demand of these rapidly dividing
cells. This marked difference in expression of the FR between healthy and cancerous cells is the basis for the selection
of the FR as a possible chemotherapeutic molecular target.
The glutamate tail of FA possess α and γ carboxylic acid moieties (Figure 1), which have markedly different
pKa values and hence different reactivities.[123, 124] The formation of folate conjugates was previously based upon
the assumption that covalent modification of one or both of the carboxylic acid moieties of FA would not adversely
affect the binding strength or affinity of the folate conjugates to the FR. In 1999, Leamon et al, determined that
macromolecules attached to folic acid by either an α or γ glutamyl linkage could associate with FR bearing cells at
virtually identical levels.[125]
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In 2013, Chen et al, successfully resolved the crystal structure of the human FRα in complex with folic acid
at 2.8 Å resolution.[80] They reported that there is a structural rationale for the absolute requirement of the pterin
group for anchoring folate in the binding pocket of the receptor and for the availability of the glutamate group for
conjugation with drugs and imaging reagents, without adversely affecting the interactions between receptor and
ligand.[80] In addition, Wibowo et al also published structures of human folate receptors α and β and described the
molecular basis for human FR in complex with antifolates Alimta, aminopterin and methotrexate.[93] More recently
Boss et al (2016), synthesized and compared the in vitro and in vivo properties of three pairs of alpha- and gammaconjugated folic acid derivatives labelled with fluorine-18 (Fig. 4).[126] They observed that all folate derivatives
displayed a high binding affinity to the FR-alpha and demonstrated by utilising in vivo PET imaging and
biodistribution studies in FR-positive KB tumour-bearing mice that both regioisomers had similar FR-specific tumour
uptake. Importantly however, the alpha-regioisomers had significantly lower FR-unspecific liver uptake whilst the
gamma-regioisomers displayed 50% lower kidney uptake compared to alpha-regioisomers. In the case of these F-18based radiofolates the site of conjugation to the glutamyl moiety of folic acid had no effect on their in vitro FR-binding
affinity but has significant impact on their in vivo biodistribution and uptake.[126]

Fig. 4. General structures and two specific examples of α- and γ‑conjugated folic acid positron emission tomography
(PET) radiotracers labelled with Fluorine-18. Summary of conjugation site impact on the in vivo behaviour of 18Fbased radiofolates, but not on in vitro FR-binding affinity.[126]
The results of this study demonstrate for the first time that conjugation position on the glutamate moiety of
18F labelled folate conjugates has no effect on the in vitro binding affinity toward the FR, but has a considerable
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impact on the in vivo distribution pattern. In addition it should be noted that the γ- conjugated folate
radiopharmaceutical 99mTc-EC20 cannot be used to detect liver metastasis due to non-specific liver uptake in
humans.[127, 128] Liver cells do not express the FR and it is plausible that this non-specific uptake could be due to
carrier-mediated uptake via organic anion transporters or proton-coupled folate transporter (PCFT).[126] Given that
the PCFT is predominately expressed in the intestines and the liver[129, 130], this non-specific uptake could
potentially be overcome with the use of α-conjugated folate pharmaceuticals and/or by the formation of cationic folate
metal complexes.

3. COORDINATION COMPLEXES OF FOLIC ACID
Inorganic medicinal chemistry, as a specific field, has a relatively short history, having its origins in the
discovery of the successful anticancer drug, cisplatin, which entered the clinic in 1978.[131] It has since been used in
the treatment of various solid neoplastic malignancies including sarcomas and carcinomas such as small cell lung
cancer, testicular, ovarian, cervical, endometrial, bladder, head and neck, gastroesophageal and germ cell
cancers/tumours.[132-134] It has proven highly effective against testicular cancer in combination with other agents
such as bleomycin with cure rates up to 85%.[135]
Cisplatin was the first platinum based solid tumour treatment and it is still extensively utilised, being a major
component in first, second and third line treatment regimens for the aforementioned cancer types.[136] The clinical
success of the platinum(II) drugs is immense, as they are among the most effective anticancer cytotoxins available
and are currently utilised in 50% of all treatment regimes for solid tumours. The development of coordination
complexes with novel structures and possessing biological activity, such as antimicrobial, anti-inflammatory,
antioxidant and anticancer, characterizes this exciting field as offering great potential to improve the quality of
life.[137-157]
Inorganic medicinal chemistry offers an alternative to organic drugs through opportunities for the design of
therapeutics that target different biochemical pathways.[158] The incorporation of metal ions into the molecular
structure of a potential drug offers the medicinal chemist an opportunity to exploit structural diversity, have access to
various oxidation states of the metal and also offer the possibility of enhancing the activity of an established organic
drug through its coordination to the metal centre.[141, 159] Various metals have been utilised for medicinal purposes
for almost 5000 years.[160-162] The sterilization of water was achieved by the Egyptians through the use of copper
(circa 3000 BC) and gold was applied to limited effect in various remedies almost 3500 years ago in China and
Arabia.[163] Around 1500 BC in Egypt, iron was used in a variety of medicines and at approximately the same time
zinc was found to aid in wound healing.[164, 165] Interdisciplinary research in the field of inorganic medicinal
chemistry is advancing our understanding of metal toxicity and enabling the design of metal-containing compounds
as effective and targeted anticancer agents with unique modes of action.
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The coordination chemistry of folic acid, which comprises a pteridine moiety linked via a methylene bridge
to para-aminobenzoic acid which in turn is attached to a glutamic acid moiety via an amide bond (Fig. 1), is not well
characterised. Metal complexes of pteridines are not common since they are highly π electron deficient heterocycles
but they are known to form some complexes involving their nitrogen and oxygen atoms (which can exist in either a
carbonyl group or an iminol group depending on which tautomeric state prevails).[166] The binding properties of
glutamic acid, on the other hand, are well established and it is known to form thermodynamically stable complexes
with a range of metals.[167] Very few articles in the literature describe the direct coordination of folate/folic acid to a
metal even though such complexes may have interesting biological activity in their own right and they may also have
affinity for the folate receptor. Table 1 summarises the formulation, mode of coordination and any reported biological
properties for the metal folate/folic acid complexes, and relevant related compounds that the authors were able to find
in the literature.
The earliest reported synthesis of a metal-folate complex found in the literature was published by a group led
by J.J. Pfiffner of Park-Davis and Company in 1947.[168] They were interested in the application of folic acid as an
“anti-anaemic factor”, and the group focused on its isolation from liver and yeast. The group also synthesized some
salts of folic acid including a silver salt of the B vitamin, which involved the reaction of an aqueous solution of folic
acid with silver nitrate to yield a yellow microcrystalline product, which they formulated as [Ag2(folate)] on the basis
of elemental analysis.[168]
In 2008, Abd El-Wahed et al reported the synthesis and thermal characterisation of simple binuclear transition
metal-folate complexes with the general formula M2L.nH2O (where M = Mn2+, Co2+, Ni2+, Cu2+, Zn2+, Cd2+ and Hg2+
; L = folate; n = 1-3,5 or 15), generated by the reaction of sodium folate with the respective metal chlorides.[169] In
these complexes the folate anion acts as a dicarboxylate ligand, where the metal ion is coordinated to the α and/or γ
carboxylate groups of the glutamic acid moiety (Fig. 5 (A)). In addition to the synthesis they also conducted antifungal
and antibacterial testing on these simple metal-folate complexes concluding that the cadmium(II), cobalt(II) and
nickel(II) folate complexes exhibit activity against Penicillium, Trichoderma and B. subtilis, while a mercury(II) folate
complex was shown to exhibit high activity against Penicillium, Trichoderma and E. coli.[169] The generation of
[Ag2(folate)].3H2O (which the authors believe to be the same as the compound reported by J.J. Pfiffner et al in 1947),
via a similar synthetic route, has also been reported recently[170]
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Fig. 5. (A) The structure of various metal folate complexes synthesized by Abd El- Wahed et al.. The structure of the
4 coordinate complexes where M = Mn2+, Co2+, Ni2+, Cu2+, Zn2+, Cd2+ and Hg2+ and n = 1, 3, 15, 2, 0, 3 and 0,
respectively. (B) The structure of the only six coordinate complex where M = Fe3+ and n = 7.[169] (C) The structure
of [(VO)2(L)(NH4)2(SO4)2].[171]
In 2016, the synthesis and characterization of a similar simple vanadium(IV) folate complex
[(VO)2(L)(NH4)2(SO4)2] was also published (Fig. 5 (C)).[171] [(VO)2(L)(NH4)2(SO4)2] was isolated from the reaction
of vanadyl(II) sulphate and folic acid in an alkaline solution and the complex was found to exhibit antioxidant and
anti-DNA damage capabilities.[171]
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Trivalent Lanthanide complexes with the general formula Ln2L3.nH2O (Ln = La3+ to Gd3+, except Pm3+; L =
folate; n = 6-9.5) have also been isolated from the reaction of the respective metal chlorides with sodium folate.[172]
Although no structure is proposed for these complexes the authors postulate that the folate is bridging the metal centres
via the carbonyl groups of the glutamate moiety. More recently, mononuclear iron and copper folate complexes, with
the general formula ML2.nH2O (M = Cu2+ or Fe3+; L = folate; n = 2 or, respectively) have been reported whereby the
metal ions are coordinated to two folate anions via the glutamate moiety which effectively acts as bidentate ligand on
the α and γ carboxylate groups (Fig. 6 (A)).[173] Using white albino mice treated with 100 mg/kg of folic acid or the
copper-/iron-folate complexes, the authors demonstrated that the complexes were more efficiently absorbed in rodent
blood than folic acid itself, which they believe may be due to the increased solubility of the metal-folate complexes.
Folate complexes, with the general formula ML.nH2O (M = Mn2+, Fe2+, Co2+, Ni2+, Cu2+, Zn2+; L = folate; n = 4-6)
have also been reported. [170, 172, 174] It is proposed that in these complexes the folate also acts as a bidentate ligand
via the glutamate moiety but their structures were not confirmed.
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Fig. 6. (A) The proposed structure of the octahedral metal (M = Cu2+ or Fe3+) difolate complexes synthesized by
Hamed et al.[173] (B) The proposed structure of the neutral complex [Cu(MTX)(H2O)] (MTX2- = dianionic
methotrexate) isolated at pH 7.5.[175] (C) The structure of [UO2(folate)2](EV)2 (EV = Ethyl Violet).[176] (D) The
proposed structure of ΔR cis-bis(2,2’-bipyridine)-dichlororuthenium(II), [cis-Ru(2,2’-bipy)2Cl2] coordinated to
positions the N5 and N10 of folic acid.[177]
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In 2015, Rojo et al reported the synthesis and characterisation of calcium and strontium folates with the
general formula ML.4H2O (M = Ca2+ or Sr2+; L = folate), in which the folate also acts as a bidentate ligand via the
glutamate moiety.[178] The strontium-folate complex, which was obtained from the reaction of the sodium salt of
folic acid with strontium chloride, was shown to have the potential to overcome the toxic effects associated with free
Sr2+ ions, a problem associated with the established anti-osteoporosis treatment regimens involving strontium renelate
as a bone promoter. Interestingly, in 2015 Nagaj et al reported the copper(II) complex of the antifolate agent
methotrexate, an analogue of folic acid (Fig. 1).[175] Potentiometric titrations of MTX against CuCl2 yielded the
neutral complex [Cu(MTX)(H2O)] (MTX2- = the doubly deprotonated methotrexate) at pH 7.5 and on the basis of
NMR and IR spectral evidence the authors proposed that the MTX2- was bound to the copper(II) centre as a tridentate
ligand via the α and γ carboxylate and the amide nitrogen functionalities (Fig. 6 (B)). [Cu(MTX)(H2O)] was also
shown to be an effective nuclease agent in the presence of added hydrogen peroxide and the complex was found to be
approximately twice as cytotoxic against mouse colon carcinoma (CT26) and human lung adenocarcinoma (A549)
cell lines when compared to the metal-free methotrexate.
During their work on developing a novel method for analyzing folic acid and its metabolites under
physiological conditions Xi et al isolated the 2:1 anionic folate-uranium(IV) complex salt [UO2(folate)2](EV)2 (where
EV+ = the cation of the basic triphenylmethane dye ethyl violet) in aqueous solution at pH 4.2-4.8.[176] Based on

charge density calculations it is proposed that in the structure of [UO2(folate)2](EV)2 that the folate ligands are
coordinated to the uranium atoms in the UO22+ moieties via the nitrogen atom of the imido-group of the aminocarboxyl and the oxygen atom of the α-carbonyl to form stable five-membered chelate rings (Fig. 6 (C)).
In 1992 Schwederski et al reported the synthesis of the ruthenium complex cation [cis-Ru(2,2’-bipy)2(FA)]2+
(FA = folic acid) in which they postulated, based on a limited analysis, that a neutral folic acid ligand was bound to
the ruthenium, as an α-iminocarbonyl chelate, via the carbonyl oxygen and a nitrogen atom of the pteridine
moiety.[179] More recently, in an effort to investigate the interaction of ruthenium complexes with intracellular
biomolecules, Scrase and colleagues reported the isolation of [cis-Ru(2,2’-bipy)2(FA)]2+ under physiologically
relevant conditions.[177] The diastereomers of the complex dication were isolated, as the hexafluorophosphate salts
subsequent to the reaction of [cis-Ru(2,2’-bipy)2Cl2.2H2O] with one equivalent of folic acid in aqueous solution. The
complex was characterised extensively by NMR and MS which revealed that the folic acid acts as a neutral chelating
ligand involving a nitrogen atom from the pteridine group and the amine nitrogen of the para-aminobenzoic acid
moiety (Fig. 6 (D)).[177] These authors also repeated the synthesis of the complexes reported by Schwederski et al
and confirmed that the two complexes were identical. In addition, the group experimented with altered protonation
states of folic acid and confirmed that the binding of the neutral folic acid was contingent on its ability to act as the
N-N chelate.
This N-N chelate mode of coordination had previously been reported in a platinum(II) complex generated
when the cis-diaminediaquaplatinum(II) cation was reacted with the reduced folate tetrahydrofolate at pH 7 and 37
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O

C to generate the pure complex in 70% yield.[180] The elemental analysis, NMR and absorbance spectroscopies

over a range of pH values were used to confirm that the diamine platinum moiety was bridged across the N5 and N10
positions of the tetrahydrofolate. Interestingly, whereas similar complexes were isolated for 5-methylhydrofolate, 5formyltetrahydrofolate, methotrexate and aminopterin, these authors reported that the diamine platinum cation did not
react with either folate and 7,8-dihydrofolate. The biological implications of these observations were also investigated
and the cis-diaminediaquaplatinum(II)tetrahydrofolate complex was found to be a reasonably good inhibitor of
dihydrofolate reductase (Ki = 4 µM) and of the folate transport system (50% inhibition at 200 µM) in the mouse
lymphocytic leukemia cells line (L1210). It is noteworthy that there is no apparent cell death caused by the cisdiaminediaquaplatinum(II)tetrahydrofolate complex at 200 µM during the folate transport inhibition study suggesting
that it would not be capable of exerting a cytotoxic response in the same way as cisplatin, possibly due to the lack of
labile coordination sites in its structure.
Two very interesting nickel(II) and cobalt(II) biomolecule-based coordination complex nanotubes (BMBCCNT’s), with the molecular formula of the monomeric unit {M2(folate)(N2H4)3(OH)2(H2O)2}f (M = Ni2+ or Co2+)
have recently been reported.[181, 182] These BMB-CCNT’s were synthesised in good yield by a method involving
ultrasonification of folic acid with the respective metal(II)chloride in a 1:2 molar ratio and with the addition of 10 mL
of aqueous hydrazine (at pH 10.5) in an ethanol/water mixture (20/80) followed by the heating in an autoclave to 120
°C to yield the product. Similar attempts to generate the Zn2+, Ca2+, Fe2+ and Cu2+, analogues were unsuccessful and
the authors reported the recovery of only the corresponding metal oxides from these reactions. The structure of the
{Ni2(folate)(N2H4)3(OH)2(H2O)2}n nanotubes (Fig. 7) was confirmed by an array of physicochemical techniques.

Fig. 7. The proposed structure of nickel(II) biomolecule-based coordination complex nanotubes (BMB-CCNT’s), with
the molecular formula of the monomeric unit being {Ni2(folate)(N2H4)3(OH)2(H2O)2}n. [182]
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The folate ligand is bound to the M2+ ions via its carboxylate groups, which act as bidentate chelates and the
nanotubes comprise a polymeric structure in which the metal ions are at the centre of octahedral coordination sphere
with hydrazine ligands bridging neighbouring M2+ to each other and with hydrogen bonding involving the pteroic
moiety of the folate forming a tape-like structure (Fig. 7). To demonstrate the importance of the hydrazine in the role
of the nanotube formation these workers also reacted folic acid with nickel(II) chloride in the presence of ammonia or
sodium hydroxide instead of the hydrazine under the same experimental conditions.[182] Using transition electron
microscopy (TEM) imaging the resulting complexes, for which the authors did not provide formulation data, were
found to form non-nanotubular structures.
The {Ni2(folate)(N2H4)3(OH)2(H2O)2}n nanotubes were tested for their activity against human cervical cancer
HeLa cells (FR+ve), human lung adenocarcinoma cancer A549 cells (FR-ve) and normal human embryonic lung
fibroblasts HELF cells (FR-ve).[182] The results showed that the {Ni2(folate)(N2H4)3(OH)2(H2O)2}n nanotubes
exhibited comparable cytotoxicity to cisplatin and that they are selective for the FR+ve HeLa cells ( IC50 = 0.586
µg/ml, 0.855 µg/ml and 10.139 µg/ml for the HeLa, A549 and HELF cell lines, respectively). The
{Co2(folate)(N2H4)3(OH)2(H2O)2}n nanotubes were also tested for their cytotoxicity and they were found to be even
more selective for the FR+ve over FR-ve cells (IC50 = 0.1.47 µg/ml, 5.43 µg/ml and 20.32 µg/ml for the HeLa, A549
and normal human liver L-O2 cell lines, respectively).[181] Further interest is derived in this class of material in that
the inner tubes of the {M2(folate)(N2H4)3(OH)2(H2O)2}n nanotubes can easily be loaded with clinical drugs such as
cisplatin or doxorubicin to yield dual action therapeutics. Cellular uptake studies demonstrated that the drug loaded
nanotubes, which are stable at physiological pH, enter cells through a FR mediated endocytic mechanism and that
they are broken down to release the active components in the acidic environment inside the cell. The fundamental
pharmacokinetic profiles and biodistribution of the {Co2(folate)(N2H4)3(OH)2(H2O)2}n nanotubes in mice are also
reported along with its very positive in-vivo antitumour activity.[181]
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Table 1: Formulae, mode of coordination and biological properties for the metal folate/folic acid complexes.
Formulae
M2(folate).nH2O (M = Mn2+, Co2+, Ni2+, Cu2+,
Zn2+, Cd2+ and Hg2+ ; n = 1-3,5 or 15)

Binding mode of the folate/folic acid
Bidentate bridging via α and γ carboxylate
groups

Biological activity
Antifungal and antibacterial activity

[Ag2(folate)].3H2O

Bidentate bridging via α and γ carboxylate
groups

None reported

[170]

[(VO)2(folate)(NH4)2(SO4)2]

Antioxidant and anti-DNA damage
capabilities.
None reported

[171]

M(folate)2.nH2O absorbed more efficiently in
rodent blood than metal-free folic acid
None reported

[173]
[170, 174]

Sr(folate).4H2O is a non-toxic bone promoter

[178]

[Cu(MTX)(H2O)] (MTX2- = the doubly
deprotonated methotrexate)
[UO2(folate)2](EV)2 (EV+ = the cation of the
basic triphenylmethane dye ethyl violet)

Bidentate bridging via α and γ carboxylate
groups
Bidentate bridging via α and γ carboxylate
groups
Bidentate chelating via the α and γ
carboxylate groups
Bidentate chelating via the α and γ
carboxylate groups
Bridging Bidentate via α and γ carboxylate
groups
Tridentate (α and γ carboxylate groups and
the amide nitrogen of the glutamate moiety)
Chelating via α carboxylate and amide
nitrogen of the glutamate moiety

Nuclease active and cytotoxicity

[175]

None reported

[176]

[cis-Ru(2,2’-bipy)2(folic acid)]2+

Chelating via N5 and N10 nitrogen atoms

None reported

[177, 179]

[cis-Pt(NH3)2(H2O)2(tetrahydrofolate)]

Chelating via N5 and N10 nitrogen atoms

Dihydrofolate reductase and folate transport
system inhibition in L1210 cell line

{M2(folate)(N2H4)3(OH)2(H2O)2}n (M = Ni2+
or Co2+)

Bidentate bridging via α and γ carboxylate
groups

FR+ve selective cytotoxicity; where M = Co2+
- in-vivo antitumour activity in mice.

Ln2(folate)3.nH2O (Ln = La3+ to Gd3+, except
Pm3+; n = 6-9.5)
M(folate)2.nH2O (M = Cu2+ or Fe3+; n = 2 or,
respectively)
M(folate).nH2O (M = Mn2+, Fe2+, Co2+, Ni2+,
Cu2+, Zn2+; n = 4-6)
M(folate).4H2O (M = Ca2+ or Sr2+)

Reference
[169]

[172]

[180]

[181, 182]
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4. FOLATE-METAL COMPLEX CONJUGATES AS TARGETED THERAPEUTIC AGENTS
As well as its ability to act as a ligand in its own right folic acid can also be conjugated to small or large
biologically active metal complexes through either direct folate coupling or folate coupling via a spacer. The inclusion
of a linker allows for effective unhindered binding of the folate moiety to the FR and control over the lipophilicity of
the folate conjugate, which are requirements for cellular internalization of the entire molecule through endocytosis
(Fig. 8). Furthermore, if required, selective delivery of a therapeutic metal complex can be achieved by the inclusion
of a suitable cleavable bond which can facilitate the dissociation of the active payload from the folate carrier once the
folate-metal complex conjugate is endocytosed. Generally, unless otherwise stated, the synthesis of the compounds in
reviewed in this section and in section 5 involve the following methods for conjugate formation: (i) the formation of
an amide bond involving the reaction of a carboxylic acid group (α and/or γ) of the glutamate moiety of the folic acid
with an amine (-NH2) functionality on the linker (generally an alkyl diamine molecule, PEG derivate or amino acid)
which in turn can be bound to the coordination complex via a second amide bond (Fig. 8); (ii) direct conjugation of
folic acid to the active metal complex via an amide bond. Alternative strategies involve encapsulation of active metal
complexes within folate-conjugated carriers.

Fig. 8. Structural design of a folate-metal complex conjugate comprising the folate targeted moiety, the optional linker
and the amide bond formation to the active metal complex.

4.1. Platinum-based systems
Platinum-based drugs play a key role in treatment regimens of a range of cancers.

However, their

applicability and efficacy are plagued by limitations regarding drug resistance and adverse toxic side effects. The
ability to selectively deliver this class of drug through targeted strategies has recently been an area of intense
research.[183-185] Table 2 summarises the structural and biological profiles of the known platinum-folate conjugate
systems.
The systematic preparations of folate conjugates of cisplatin and carboplatin were recently reported.[186]
The multi-step synthesis involved the direct attachment of diamine and dicarboxylate functionalities to the glutamate
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moiety of folic acid followed by reaction with the respective platinum(II) salts to yield five different derivatives (Fig.
9). Although this approach yielded desirable structures, the folate-complex conjugates were not studied for their
cytotoxicity or FR uptake capabilities due to their poor solubility.

Fig. 9. The general synthetic scheme of folate-conjugates of cisplatin-like and carboplatin-like complexes.[186]
Many attempts have been made to enhance the therapeutic potential of platinum anticancer drugs through
their conjugation to large polymeric carrier molecules such as polyethyleneglycols (PEG’s) which are known to
increase their solubilities in water.[185] Although this approach can significantly improve pharmacokinetics and
tissue distribution of the drug, cell permeability can remain a problem due to the relatively high molecular weights of
such conjugates.[187] This poses a particular problem for platinum complexes in that if they are released in the
extracellular medium, they can act as nonspecific electrophiles, and then be rapidly inactivated by extracellular
nucleophiles. To address this issue Aronov et al prepared the carboplatin conjugate FA-PEG-Carboplatin (Fig. 10 (A))
and studied its cellular uptake, its effect on the rate of DNA platination and its relative cytotoxicity.[188] They also
synthesized the fluorescent analogue FA-PEG-FITC (FITC = fluorescein isothiocyanate) to enable them to explore
the effects of the conjugation on the cellular uptake of the PEG system using confocal microscopy and fluorescenceassisted cell sorting (FACS). The synthesis of the FA-PEG-Carboplatin is arduous, involving six steps, and requiring
significant purification and characterization. Indeed, the authors claim this to be the first time a complete chemical
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characterization of Pt-PEG conjugates was undertaken, involving 1H NMR,
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Pt NMR, and 2D-[1H,
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N]

heteronuclear single quantum correlation (HSQC) spectroscopy.

Fig. 10. (A) The structure of the FA-PEG-Carboplatin conjugate.[188] (B) The proposed structure of a single unit of
the folate conjugate Cisplatin-FA-PEG-g-PAsp-Ami polymer.[189] (C) The proposed structure of a platinum(IV)
containing a folate derivative (FA) at an axial position, attached to the surface of an amine-functionalized singlewalled carbon nanotube (SWNT-PL-PEG-NH2) through multiple amide linkages.[190]
Using a folate receptor-enriched cell line, M109HiFR, these researchers conducted drug uptake and
cytotoxicity studies as well as the determination of Pt-adduct formation. Results showed that the folate-targeted FAPEG-Carboplatin conjugate was less cytotoxic than both its untargeted PEG-Carboplatin counterpart and the free drug
carboplatin, despite exhibiting increased drug uptake via endocytosis. The untargeted PEG-Carboplatin conjugate
produced higher levels of DNA binding than the folate-targeted FA-PEG-Carboplatin conjugate, thus accounting for
its low cytotoxicity. It was suggested that this unexpected phenomenon may be due to the folate receptor-mediated
endocytic pathway, in which folate-conjugates are not released into the cytosol but rather are directed to acidic
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lysosomes or endosomes, thereby limiting access to the nucleus. The findings suggest that the folate-targeted
conjugate FA-PEG-Carboplatin may be unsuitable as a prodrug for the carboplatin family, as the conjugate appears
to be neutralized or blocked during the folate receptor-mediated endocytosis process, resulting in entrapment of the
prodrug in certain cellular compartments. The authors concluded that folate targeting may not be an appropriate
delivery system for Pt-based drugs as the active moieties may become neutralised or hindered by the folate receptormediated endocytic system.
In an attempt to reduce toxic side effects while enhancing its antitumor activity the incorporation of cisplatin
into a polymeric folate conjugate with PEG-graft-α,β-poly[(N-amino acidyl)-aspartamide] (Cisplatin-FA-PEG-gPAsp-Ami) has also been studied recently (Fig. 10 (B)).[189] The targeted polymer-metal complex micelles were
prepared by stirring cisplatin with the FA-PEG-g-PAsp-Ami in distilled water for 24 hours at 37 oC, followed by
purification by dialysis and characterization by measurement of critical aggregation concentration, particle size and
morphological observations. Cytotoxicity was determined in the oral cancer KB cell line (FR+ve), by treating the
cells with the folate targeted Cisplatin-FA-PEG-g-PAsp-Ami and untargeted Cisplatin-PEG-g-PAsp-Ami complexes
in folate deficient media for 24 h. The results showed that the folate-conjugated complex was far more cytotoxic (50%
cell viability at 100 µg/ml concentration) to the cell line than the non-targeted system (> 60% cell viability at 100
µg/ml concentration), due to folate receptor mediated endocytic uptake of the compound. Additional inhibition assays
using excess folic acid supported the role of FR targeting for the Cisplatin-FA-PEG-g-PAsp-Ami (70% cell viability
at 100 µg/ml concentration in the presence of 1 mg/ml of added folic acid). In vivo testing in male athymic mice
exhibited similar results, indicating that Cisplatin-FA-PEG-g-PAsp-Ami micelles were well tolerated by the mice, and
exhibited great potential as tumour targeted cisplatin alternatives.
In 2012, Chaudhury et al reported the use of intraperitoneal (IP) administration coupled with a folate receptortargeted (FRT) liposomal system intended to achieve intracellular delivery of carboplatin with a view to increasing
the therapeutic efficacy and reducing toxicity of the drug for the purpose of IP treatment of ovarian cancer.[191] The
authors discussed the limitations of IP administration of chemotherapy and the advantages of a drug delivery system
such as an FR targeted liposomal system, which could deliver a drug payload into ovarian cancer cells. Initial
fluorescence studies on IGROV-1 cells before injection showed a twofold increase in cellular accumulation of the
folate targeted platinum compared to the non-targeted carboplatin. From here, cytotoxicity studies showed that a
concentration as low as 13 μM of folate-targeted carboplatin could induce cell death in 50% of IGROV-1 cells in
vitro, while both the free drug and non-targeted conjugate required 24 – 45 μM respectively. The authors also used an
intraperiotenally grown human IGROV-1 ovarian tumor xenograft mouse model (selected to mimic the clinical nature
of tumour burden in women with advanced-stage ovarian cancer and overexpression of FR). These in-vivo studies
identified that 5 out of 6 FR targeted carboplatin liposome treated mice (83%) survived to the end of the study, whereas
the non-targeted carboplatin treated liposome group, free drug or saline treated control all died within 19-39 days posttumour inoculation. Of the 83% mice that survived treatment, none showed weight-loss or metastasis. The authors
concluded that intraperitoneal (IP) administration of folate-targeted carboplatin liposomes has the potential to extend
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the overall survival of ovarian cancer patients as well as maintaining therapeutic efficacy with reduced risk of regimenrelated toxicities.
A similar strategy was also reported for the targeted delivery of a mixture of the arsenic- and platinum-based
drugs in a single folate-functionalised liposome.[192] The co-encapsulation of [As(OH)3] and [Pt(NH3)2(H2O)2]2+ in
the folate-functionalised liposome, which the authors refer to as a ‘nanobin’, facilitated efficient delivery of the
anticancer drug combination with preferential uptake in the KB nasopharyngeal cell line (FR+ve) compared to MCF7 breast cancer cells (FR-ve).
Folate conjugated nanogels (swollen polymers containing ca. 95% water), which have very high loading
capabilities, have also been demonstrated to be effective targeted delivery systems for cisplatin with preferential
uptake in A2780 human ovarian carcinoma cells (FR+ve) and superior antitumour activity towards A2780 xanografts
in contrast to cisplatin on its own.[193] FR mediated endocytosis has also been achieved when [Pt(NH3)2(H2O)2]2+ ,
folic acid and rhodamine B isothiocyanate were conjugated onto magnetic calcium phosphate nanoparticles, with its
cytotoxicity being fourfold and onefold more active against HeLa human cervical cancer cells (FR+ve) and L929
human cervical cancer cells (FR-ve), respectively, when compared to the activities of [Pt(NH3)2(H2O)2]2+ on its
own.[194]
An interesting approach to targeting platinum drugs towards cancer cells was reported by Lippard et al by
attaching the folate-PEG derivative c,c-t-[Pt(NH3)2Cl2(O2CCH2CH2CO2H)(O2CCH2CH2CONH-PEG-folate)] (Fig. 10
(C)) to the surface of an amine-functionalised single-walled carbon nanotube (SWNT) via multiple amide bonds to
yield c,c-t-[Pt(NH3)2Cl2(O2CCH2CH2CONH-SWNT)(O2CCH2CH2CONH-PEG-folate)].[190]

The folate-PEG

complex c,c-t-[Pt(NH3)2Cl2(O2CCH2CH2CO2H)(O2CCH2CH2CONH-PEG-folate)] was shown to preferentially target
FR+ve (human nasopharyngeal carcinoma KB) over the FR-ve (testicular carcinoma NTera-2) cell lines. The
cytotoxicity of c,c-t-[Pt(NH3)2Cl2(O2CCH2CH2CO2H)(O2CCH2CH2CONH-PEG-folate)] was significantly enhanced
when it was tethered to the SWNT (IC50 improved from 0.15 to 0.01 µM in the KB cells), which facilitates its delivery
via folate receptor mediated endocytosis (FRME). The FRME mode of cell internalisation was confirmed when a
fluorescein-based fluorophore was attached to c,c-t-[Pt(NH3)2Cl2(O2CCH2CH2CONH-SWNT)(O2CCH2CH2CONHPEG-folate)], with the florescent derivative being observed inside the endosomes using fluorescence microscopy.
Once the c,c-t-[Pt(NH3)2Cl2(O2CCH2CH2CONH-SWNT)(O2CCH2CH2CONH-PEG-folate)] enters the cell it is
reduced to deliver the Pt(II) drug cisplatin [Pt(NH3)2Cl2], thus avoiding the complications normally associated with
the delivery of cisplatin under clinical conditions, and also with the added advantage of increasing the amount of
cisplatin delivered into the cell. The release of the active cisplatin inside the cell was confirmed by the observation
that Pt-1,2-d(GpG) intrastrand cross-links were formed with the nuclear DNA in KB cells.

The c,c-t-

[Pt(NH3)2Cl2(O2CCH2CH2CONH-SWNT)(O2CCH2CH2CONH-PEG-folate)] was found to be 8.6 times more active
against FR+ve (human choriocarcinoma JAR and human nasopharyngeal carcinoma KB cell lines) than the FR-ve
testicular carcinoma NTera-2 cell line. Although the concept of tethering FR-targeted conjugates to SWNT’s to
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increase their cellular uptake is very interesting the toxicity of SWNT’s is an issue that needs to be considered in any
clinical applications.[195]

Here

4.2. Non-platinum systems
The anticancer properties of gallium(III) compounds have been attracting attention since the 1970’s. The

mechanism through which Ga(III) induces cell death (involving DNA binding/modification, enzyme inhibition and
ion transport disruption) has been extensively investigated however the pharmokinetic properties of gallium salts
prevent their widespread chemotherapeutic use, some of which include renal retention time and cancer cell targeting.
To explore the cancer cell targeting abilities of gallium(III) complexes, Viola-Villegas et al studied the conjugation
of the gallium(III) complexes of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), via a polyethylene
glycol (PEG) linker, to the γ carboxylic acid moiety of folic acid (Fig. 11 (A)).[196] The authors determined the IC50
concentrations for the Gallium(III) containing compounds in both A2780/AD (Adriamycin resistant ovarian cancer
cell line which overexpresses FR) and CHO cells (non FR-expressing cell line), with the IC50 being lower in the
A2780/AD cells in all cases. These studies revealed two interesting results; (i) the metal-free conjugate and its gallium
complex were both toxic towards the CHO cells and (ii) the metal-free γ-FA-PEG-HDOTA showed greater
cytotoxicity (IC50 = 1.35 and 0.18 mM for the CHO and A2780/AD cell lines, respectively) than its coordinated
counterpart, γ-FA-PEG-Ga(HDOTA) ((IC50 = 2.93 and 1.85 mM for the CHO and A2780/AD cell lines, respectively).
To explain this unexpected toxicity, researchers concluded that gallium was ‘leaking’ from the Ga-DOTA moiety,
allowing the ligand to chelate other metals in the cellular environment. Additional stability studies carried out in
HEPES buffer and RPMI 1640 media over 72 hours coupled with HPLC and ICP techniques supported this theory.
Unfortunately, as the non-complexed γ-FA-PEG-(HDOTA) showed greater cytotoxicity than its gallium-containing
counterpart, the folate conjugate γ-FA-PEG-Ga(HDOTA) was considered to be unsuitable as an anti-cancer agent.
However, the authors did indicate that by coupling the γ-emitting 67Ga isotope or β-emitting 68Ga isotope to the FAPEG conjugate, it may be possible to use this approach to generate a suitable diagnostic agent.
The water-soluble folate conjugate of zinc tetraaminophthalocyanine (ZnaPc-folate) was recently reported
(Fig. 11 (B)).[197, 198] The study of the photophysical and photochemical properties of ZnaPc-folate revealed that
an increase in the fluorescence quantum yield of the conjugate was accompanied by a decrease in the triplet and singlet
oxygen quantum yields, a decrease that was not observed when ZnaPc was simply mixed with folic acid (in the absence
of formal conjugation).[197] Confocal laser scanning microscopy (CLSM) was employed to determine that ZnaPcfolate was significantly internalised in the FR+ve KB cell line when compared to the FR-ve A549 cells, and the results
from competitive binding studies using folic acid pointed a FRME cellular uptake mechanism.[198] Whereas, ZnaPcfolate was found to be effectively inactive against KB cells in the absence of any photo-iradiation, irradiation with
two-photon excitation (TPE) of near-infrared (NIR) laser pulses caused a 10-fold decrease in cell viability when
compared to the results for sulphonated aluminium phthalocyanine (AlPcS), an approved photosensitizer for clinical
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applications under common one-photon excitation of red light.[198] The authors suggest that ZnaPc-folate represents
a promising new generation of photosentizers for TPE-based photo-dynamic therapy (PDT).

Fig. 11. (A) The proposed structure of gallium(III) complexes coordinated via DOTA and a polyethylene glycol linker
to the γ carboxylic acid moiety of folic acid, γ-FA-PEG-Ga(HDOTA) synthesized by Viola-Villegas, Vortherms and
Doyle. (FA = Folic acid, PEG = Polyethylene glycol, DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
acid).[196] (B) Proposed structure of the water-soluble folate conjugate of zinc tetraaminophthalocyanine (ZnaPcfolate) or ZnTAPcFA.[197]
In 2015, Gou and colleagues explored the use of a folate-functionalised human serum albumin (FA-HSA)
carrier system as a FR targeted delivery system for copper(II) complexes incorporating plumbagin, bypyridine and
1,10-phenanthroline ligands (Fig. 12).[199] Plumbagin is a natural small molecular naphthoquinone analogue isolated
from the medicinal plant Plumbago zeylanica and which exhibits moderate anticancer activities in vitro and in
vivo.[200-202] The FA-HAS-Cu complex systems were generated by incubating the copper(II) complexes with the
FA-HSA conjugate in BPS media and DMSO (0.5%) and the binding of the complexes, which is believed to occur in
the subdomain IIA of the protein, was confirmed by measuring fluorescence quenching associated with the HSA. The
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binding constants for the FA-HSA to the copper(II) complexes (K ~ 105 M-1) is relatively low and the authors pointed
out that this was a potential weakness with respect to the efficiency of the delivery of the complexes.

Fig. 12. Structures of various Cu(II) plumbagin polypyridyl complexes investigated by Gou et al.[199] Adapted from
Gou et al.[199]
To determine the FR specific cytotoxicity of the complexes, a number of mammalian cell lines were used
(FR+ve cell lines, HeLa and MCF-7 and FR-ve cell line WI-38). Whereas, the Cu(II) complexes themselves were
equally cytotoxic towards the FR+ve and FR-ve cells lines (IC50 range = 3-8 µM) the FA-HSA-copper complex
systems were approximately three times more active against the FR+ve cells (IC50 range = 0.98-3.67 µM) than the
FR-ve cell line (IC50 range = 3.95-6.95) µM.

The FA-HSA-copper complex system incorporating the [Cu

(PLN)(phen)]+ (where PLN = the plumbagin anion, (Fig 12 (3)) was the most cytotoxic and further studies revealed
that in HeLa cells it caused mitochondrial damage through production of reactive oxygen species (ROS) and inhibited
the activity of cyclin-dependent kinase-1 (CDK1) and the prosurvival Bcl-2 proteins leading to apoptotic cell death.
The targeted therapeutic properties of the relatively few non-platinum folate-metal complex conjugates
discussed have been summarized in Table 3.

5. FOLATE-METAL COMPLEX CONJUGATES AS TARGETED DIAGNOSTIC AGENTS
The advent of theranostic systems, containing a targeted drug coupled to an imaging agent, has been a key
development in modern medicine, particularly in the treatment of cancer. This advancement would not have
materialised if it were not for the significant successes achieved in the fields of molecular imaging and in the expansion
of the knowledge-base of the synthesis of efficient targeting compounds.[203]
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The deployment of luminescent metal complexes offers an appealing capability for cell imaging because of
the specific properties of luminescence emission from the excited states of the metals.[204] Lanthanides, Europium
in particular, have luminescent properties when bound to organic, chelating ligands. In addition, europium offers an
array of advantages such as exhibiting long emission times, enabling time-resolved measurements while narrow,
intense absorption bands ensure high colour purity. Luminescent lanthanide complexes (LLC) such as europium
complexes offer increased loading capabilities as they do not exhibit the self-quenching properties that are often
observed for organic dyes. Various LLCs can be generated from the same ligand and can thus be excited by the same
wavelength. Furthermore, the complexes synthesised often show high chemical, thermal, kinetic and photo-physical
stability while exhibiting low toxicity when compared to gadolinium complexes commonly used as contrast agents in
magnetic resonance imaging (MRI).[205] Therefore, it is unsurprising that they may prove to be highly sensitive
luminescent probes in biomedical studies. Indeed, a series of effective luminescent europium(III) complexes
exhibiting optical imaging capabilities for subcellular structures such as mitochondria, endoplasmic reticulum and
lysosomes of a variety of mammalian cell lines, has recently been reported.[206] Reports of folate-targeted
luminescent probes are scarce in the literature.
In 2012, Pavich et al synthesised the folic acid-europium chelate conjugate [FA-(phen)Eu(BTA)3] (FA(phen) = Folate-spcer-1,10-phenanthroline conjugate; BTA = benzoyl trifluoroacetone) (Fig. 13 (A)).[207] In addition
to completing studies of the absorption and luminescence spectra, as well as the luminescence excitation of the newly
formed complex, the group conducted cellular uptake studies using the FR+ cell line, HeLa. Binding of the conjugate
by the cells was determined from the intensity of europium luminescence in HeLa cell lysates. Cells were treated with
the europium conjugate for 3 hours, washed in ice cold PBS and lysed in 0.1% Triton X-100. Results indicated
significant quantities of the europium conjugate (4 X106 conjugate molecules per cell) per cell. However, the
methodology used limits the interpretation as to whether the conjugate was internalised by the cells or whether it was
bound to the cell surface. The addition of exogenous folic acid severely reduced the binding of the molecules by 68%,
suggesting that the folate receptor localized on the cell surface is binding to the conjugate.[207] These results and the
observed promising luminescent timeframe of 110 μs may serve to spearhead the design of selective methods for timeresolved luminescent microanalysis based on conjugates of folic acid with europium complexes. However, the
characterisation of the [FA-(phen)Eu(BTA)3] was poor and no data regarding the cytotoxicity or stability of the
conjugate were reported.

27

Medicinal inorganic folate receptor-targeted compounds

Fig. 13. (A) The structure of the conjugate FA-(Phen)Eu(BTA)3. (Phen = 1,10-Phenanthroline, BTA = benzoyl
trifluoroacetone).[207] (B) Structure of the Cu corrole, Gd DOTA folate complex.[208]
The gadolinium(III) complex of DOTA is currently used as an extravascular contrast agent for MRI.[209]
Recently, a number of bifunctional imaging contrast agents incorporating DOTA and porphyrin macrocycles have
been reported.[210, 211] In 2015 Gros et al reported the synthesis and characterisation of a heterobimetallic copper(II)
corrole/gadolinium(III) DOTA-folate complex (Fig. 13 (B)) as a potential FR-targeted bifunctional contrast agent for
MRI and positron emission tomography (PET) imaging of cancer.[208] The complex was obtained in high yield by
means of a five step synthesis.
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Fig. 14. Synthetic details and the structures of the three Europium complexes Eu3+C1, Eu3+C2 and Eu3+C3 coordinated
via DOTA to various conjugation sites of folic acid (DCC = dicyclohexylcarbodiimide; py = pyridine; DMSO =
dimethylsulphoxide; Eu3+C4 was synthesised as previously reported.[212]
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Preliminary studies showed that the relaxivity of the heterobimetallic copper(II) corrole/gadolinium(III)
DOTA-folate complex was higher in comparison to the commercially available MRI contrast agent
[Gd(DOTA)(H2O)]-. The authors did not report any data for the toxicity, cellular uptake or FR specificity of the
complex.
Also in 2015, Quici and colleagues reported the results of a more thorough study of the three water-soluble
europium complexes conjugated via 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to αcarboxylate, the γ-carboxylate and N10 (the nitrogen of the para-aminobenzoic acid group) positions of folic acid
(denoted Eu3+C1, Eu3+C2, Eu3+C3, respectively) as luminescent probes for the selective targeting of cancer cells (Fig.
14).[212] The α- and the γ-carboxylate conjugates Eu3+C1 and Eu3+C2 were generated, as a regioisomeric mixture, as
shown in Fig. 14, they were separated as pure isomers by HPLC and identified by ESI mass spectrometry. Eu3+C3
required a seven step synthesis and it was also obtained in a pure state. Synthesising one Eu complex ligated via the
α-carboxyl group of folic acid (complex 1, Eu3+C1), one via the γ-carboxyl group (complex 2, Eu3+C2) and one via
the nitrogen of the para-aminobenzoic acid group (complex 3, Eu3+C3) as depicted in Fig. 14. Stability studies on
Eu3+C1, Eu3+C2, Eu3+C3 were conducted by incubating all three conjugates in phosphate buffered saline (PBS), cell
culture medium and rat serum at 37oC for 25 hr and revealed that varying media did not affect either conjugate
luminescence or spectral shape. Cytotoxicity assays and internalisation studies conducted on a range of FR+ve ovarian
cancer cell lines indicated that all three conjugates were only cytotoxic at concentrations above 300 μM and that
internalisation was both concentration and time dependent. A negative test with the FR-ve cell line A2780 showed no
internalisation, indicating that the uptake was folate receptor mediated. Furthermore, all three conjugates complexes
Eu3+C1, Eu3+C2, Eu3+C3 were found to be extremely stable over time and after cell exposure and internalisation, with
no apparent biotransformation and no significant interaction occuring with serum protein.
Acknowledging recent discoveries regarding the FR binding site and the importance of the pterin head in
receptor recognition as well as literature disputing the need for a free α-carboxyl group for adequate receptor binding,
the group also studied the relationship between conjugation site and recognition capabilities of the conjugates by the
FR.[80, 213, 214] The cellular uptake of Eu3+C1, Eu3+C2, Eu3+C3 was found to be receptor dependent with correlation
between the uptake and FR expression. The conjugation site was also found to be a critical factor with the binding
affinity following the order Eu3+C2 > Eu3+C1 > Eu3+C3 in the SKOV-3 cell line, highlighting the importance of the
pterin head and para-aminobenzoic acid body of folic acid in receptor recognition. Furthermore, both folic acid and
Eu3+C2 were found to have equal ability to inhibit the binding of radio-labelled folic acid.
In another recent study Plush et al examined the influence that the length of the linker between the folate
head and the lanthanide-DOTA chelate had on FR mediated uptake.[215] They synthesised and characterised watersoluble folate-targeted lanthnide probes (Ln(III) = Eu(III), Tb(III) or Gd(III)) in which the Ln(DOTA) moieties were
connected to the folate heads via an aliphatic (–CH2-)n chain (where n = 1 or 5) (Fig. 15).
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Fig. 15. Structures of the water-soluble folate-targeted lanthnide probes (Ln(III) = Eu(III) or Gd(III)) in which the
Ln(DOTA) moieties were connected to the folate heads via an aliphatic (–CH2-)n chain (where n = 1 or 5).[215]
Dual action imaging agents are currently attracting significant attention.[216, 217] In 2011 Yang et al
reported the facile synthesis of the water-soluble terbium(III)DTPA-folate-Fe3O4 nanoparticle conjugates (denoted as
Tb:1b-FA-NP’s) (Fig. 16) (DTPAH3 = diethylenetriaminepentaacetic acid; and the linkers between the TB;1b and NP
moieties are polyethyleneglycol chains (PEG’s).[218]
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Fig. 16. Structure of a terbium(III) complex, Tb:1b-FA-NPs coupled to Fe3O4 magnetic nanoparticles and ligands 1b
and a 2-hydroxybenzoate derivative of Folic acid.[218]
Tb:1b-FA-NP’s were strongly luminescent in aqueous solution and they have a long fluorescence lifetime.
Cellular uptake studies, using confocal microscopy, on FR+ve Hela and FR-ve MCF-7 cells revealed that the
conjugates were preferentially taken up by the FR expressing HeLa cells in-vitro. Tb:1B-FA-NP’s was non-toxic to
the HeLa cells (up to 160 µM) and they also exhibited superparamagnetic properties upon entering the HeLa cells
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where they were shown to provide significant contrast enhancement in magnetic resonance imaging (MRI) images.
The authors propose that this class of Tb:1B-FA-NP’s have potential applications as agents for both fluorescence cell
imaging and MRI.
Along with PET, single photon emission computed tomography (SPECT) is another highly sensitive cancer
imaging technique which has attracted significant interest in the development of folate-based tracers to target FR
expressing cancers, an area that has been previously reviewed.[219-221] For the development of folate-conjugates of
such nuclear imaging agents 99mTc has emerged as the preferred radionuclide for applications in SPECT. One of the
best studied examples of such FR-targeted technecium radionuclides in 99mTc-EC20 in which

99m

to a peptide (Cys-Asp-Dap-D-Glu-Pte) which is linked to a folate moiety (Fig. 17 (A)).[128]

99m

Tc(V) is complexed

Tc-EC20 was found

to be an excellent imaging agent, with very high tumour uptake in a mouse model and the results were similar when
it was screened in clinical trials.[127] The study found that a single intravenous injection of 99mTc-EC20 resulted in
detectable uptake (measured using planar scintigraphy or SPECT) in 68% of patients and was well tolerated by the
adult patients tested. Consequently, the authors suggested that 99mTc-EC20 imaging was a safe, non-invasive procedure
that may identify FRs in recurrent or metastatic disease without the need for biopsy.[127]

Fig. 17. (A) Structure of folic acid radioconjugate,

99m

Tc-EC20.[128] (B) Structure of a new

99m

Tc-folic acid

radiotracer prepared using [99mTcN(PNP)]2+ metal fragment.[222]
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However, accumulation of 99mTc-EC20 in the kidneys and bladder, due to the presence of high FR expression
in these tissues, caused problems with very significant renal uptake of radioactivity. This problem can be ameliorated
to a significant extent by pre-treatment with antifolates such as pemetrexed.[223] However, this strategy is not ideal
as it exposes diseased patients to further stress. In recent years there have been several attempts to improve the efficacy
of 99mTc-labeled folate conjugates by modifying the nature of the linkers, the chelating agents and the radiosynthon
but the problem with high accumulation in the kidneys has persisted due to the highly hydrophobic nature of the 99mTclabeled folate conjugates.[224, 225]

In 2017 Banerjee et al reported the synthesis and biological evaluation of a

99m

Tc-labeled folate conjugate with the lipophilic [99mTcN(PNP)]2+ inorganic moiety {where N(PNP) = N-

(2methoxyethyl)-2-(diphenylphosphino)-N-(2-diphenylphosphino)ethyethanamine} (Fig. 17 (B)).[222] The

99m

Tc-

labeled folate conjugate was constructed by attaching a cysteine-based (O-S) bifunctional chelating group to the γcarboxylic acid function of folic acid to yield the targeted vector, which in turn acts as a O-S chelate upon
complexation with [99mTcN(PNP)]2+, yielding the [99mTcN(PNP)]2+-folate conjugate (Fig. 17 (B)).

The

[99mTcN(PNP)]2+-folate conjugate was found to be significantly lipophilic ( LogPo/w = 0.87). In vitro studies on FR
expressing KB-31 cells unfortunately revealed that this new

99m

Tc-labeled folate conjugate had less affinity

(approximately 10-fold) for the FR than native folic acid. However, in vivo studies involving normal Swiss mice
revealed that the [99mTcN(PNP)]2+-folate conjugate was effectively cleared from through the kidneys which is in itself
a significant development. The authors propose that the inclusion of an appropriate aliphatic spacer in the structure of
the [99mTcN(PNP)]2+-folate conjugate as a possible route to improving the FR uptake of this class of potential
radiotracer.
Table 4 summarises the structural and biological profiles for folate-metal complex conjugates with targeted diagnostic
potential.
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Table 2: The structural and biological profiles for FR targeted platinum anticancer conjugates.
FR Targeted Platinum-Based Anticancer Conjugates
Conjugate type

Linker

Active Component

Cellular Uptake
studies

In-Vitro Activity

In-Vivo Activity

Ref.

Folate-cisplatin

aliphatic diamine

Cisplatin

None reported

None reported

None reported

[186]

Folate-carboplatin

aliphatic amine

Carboplatin

Folate-PEG-carboplatin

polyethyleneglycol

Carboplatin

Confirmed by
confocal
microscopy and
FACS

Reduced
cytotoxicity in
FR+ve M109HiFR
cell line when
compared to nontargeted analogue.

None reported

[188]

Cisplatin-folate-PEG-g-PAspAmi micelles

PEG-graft-α,β-poly[(Namino
acidyl)aspartamide]

Cisplatin

Confirmed by
cytotoxicity assays
in presence of
excess folic acid

Superior
cytotoxicity
compared to nontargeted CisplatinPEG-g-PAsp-Ami
micelles in FR+ve
KB cell line.

Athymic mice:
similar results to
in vitro study with
low toxicity.

[189]

Carboplatin-folate-liposome

None: folate coupled
directly to the liposome

Carboplatin

Confirmed using
IGROV-1 cells (2fold increase in
cellular
accumulation
compared to
carboplatin)

2-fold increase in
cytotoxicity in
IGROV-1 cells
compared to
carboplatin

IGROV-1 ovarian
tumour xenograft
mice: Low
toxicity and
increased survival
rate (83%)
compared to
carboplatin

[191]

[As(OH)3]/[Pt(NH3)2(H2O)2]2+
-folate-liposome

None: folate coupled
directly to the liposome

[As(OH)3] and

Preferential uptake
in FR+ve KB cells
when compared
with FR-ve MCF-7

Attenuated
cytotoxicity
towards FR+ve

None reported

[192]

[Pt(NH3)2(H2O)2]2+
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cells

tumour cells

Cisplatin-folate-nanogels

None: folate coupled
directly to the nanogel

Cisplatin

Preferential uptake
in FR+ve A2780
cells compared to
FR-ve A549 cells

Superior
cytotoxicity
compared to nontargeted Cisplatin in
A2780 cells

A2780
xenografted mice:
Superior
cytotoxicity
compared to nontargeted Cisplatin

[193]

[Pt(NH3)2(H2O)2]2+/rhodamine
B isothiocyanate- folatemagnetic calcium phosphate
nanoparticles

None: folate coupled
directly
to
the
nanoparticles

[Pt(NH3)2(H2O)2]2+

Preferential uptake
in FR+ve HeLa cells
compared to FR-ve
L929 cells

4-fold and 1-fold
more active against
FR+ve HeLa and
FR-ve L929
,compared to
[Pt(NH3)2(H2O)2]2+

None reported

[194]

c,c-t[Pt(NH3)2Cl2(O2CCH2CH2CO
NHSWNT)(O2CCH2CH2CONHPEG-folate)]

The
Pt(NH3)2Cl2(O2CCH2CH
2CONH-SWNT) moiety
is coupled to the folate
via a PEG spacer

Cisplatin

Preferential uptake
in FR+ve KB and
JAR cells compared
to FR-ve NTera-2
cells

8.6-fold increase in
activity against KB
cells compared to
cisplatin.

None reported

[190]

Table 3: The structural and biological profiles for FR targeted non-platinum anticancer conjugates.
FR Targeted Non-Platinum Anticancer Conjugates
Conjugate type

Linker

Active Component

Cellular Uptake
studies

In-Vitro Activity

In-Vivo Activity

Ref.

γ-Folate-PEG-Ga(HDOTA)

polyethyleneglycol

Ga(HDOTA)

None reported

γ-Folate-PEGGa(HDOTA) is 2fold and 10-fold

None reported

[196]
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less cytotoxic than
metal-free γ-FolatePEG-(HDOTA) in
FR+ve A2780/Ad
and FR-ve CHO.
Folate-HSA[Cu(PLN)(phen)]+

HSA

[Cu(PLN)(phen)]+

None reported

Folate-HSA[Cu(PLN)(phen)]+
approximately 3
times more active
against the FR+ve
Hela and MCF-7
cells than the FR-ve
WI-38 cell line.

None reported

[199]

None: folate coupled
directly to the
tetraaminophthalocyanin
e

ZnaPc-folate upon
photo-irradiation

FRME Confirmed
by confocal laser
scanning
microscopy in
competitive binding
studies using folic
acid involving
FR+ve KB and FRve A549 cells

10-fold decrease in
cell viability
compared to results
for sulphonated
aluminium
phthalocyanine
(AlPcS), an
approved
photosensitizer for
clinical applications
under common onephoton excitation of
red light

None reported

[197],

(HSA = human serum albumin;
PLN = plumbagin; phen = 1,10phenanthroline).

ZnaPc-folate
(aPc = tetraaminophthalocyanine

[198]
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Table 4: The structural and biological profiles for folate-metal complex conjugates with targeted diagnostic potential.
FR Targeted metal complexes as diagnostic agents
Conjugate type

Linker

[FA-(phen)Eu(BTA)3] (FA-(phen) =
Folate-spcer-1,10-phenanthroline
conjugate; BTA = benzoyl
trifluoroacetone)

ethylenediamine

Eu3+C1, Eu3+C2, Eu3+C3, (europium
complexes conjugated via 1,4,7,10Tetraazacyclododecane-1,4,7,10tetraacetic acid (DOTA) to αcarboxylate, the γ-carboxylate and
N10 positions of folic acid,
respectively

Tetraazacyclododecane1,4,7,10-tetraacetic acid
(DOTA)

FA-NH–(CH2)n-NH-[Ln(DOTA)]
(Ln(III) = Eu(III), Tb(III) or Gd(III));
n = 2 or 6)

The diamine chain
-NH–(CH2)n-NH-

Tb(III)DTPA-folate-Fe3O4
nanoparticle conjugates (denoted as
Tb:1b-FA-NP’s)(DTPAH3 =
diethylenetriaminepentaacetic acid)

The linkers between the
TB;1b and NP moieties
are polyethyleneglycol
chains (PEG’s)

Active

Cellular Uptake

Component

studies

[FA-

Luminescence
measurements in
FR+ve HeLa cells
and competitive
binding studies
with Folic acid

None reported

Uptake in FR+ve
SKOV-3 cells was
conjugation
dependent
(Eu3+C2>Eu3+C1>
Eu3+C3) with no
uptake in FR-ve
A2780 cells.

Non-toxic

[Ln(DOTA)]3+

Effectively
internalised by
FR+ve HeLa cells
with the shorter
linker yielding
superior uptake

[Tb(DTPA)]3+

Preferential uptake
in FR+ve HeLa
over FR-ve MCF-7
cells

(phen)Eu(BTA)3]

In-Vitro Activity

below

In-Vivo Activity

Ref.

None reported

[207]

None reported

[212]

None reported

None reported

[215]

Non-toxic to HeLa
cells up to 160 µM

None reported

[218]

300µM

Superparamagnetic
in HeLa cells with
effective contrast
enhancement
in
MRI as well as
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luminescence
Heterobimetallic
Cu(II)
corrole/Gd(III)
DOTA-folate
complex (potential dual active (MRI
and PET imaging)

ethylenediamine

99m

99m

Tc-EC20 (SPECT imaging
agent)

[99mTcN(PNP)]2+-O-S-folate
conjugate {N(PNP) = N(2methoxyethyl)-2(diphenylphosphino)-N-(2diphenylphosphino)ethyethanamine}

[Cu(corrole)]2+

None reported

None reported

None reported

[208]

Extensively
studied with very
high
cellular
uptake in FR-ve
cell lines in-vitro

Low cytotoxicity

Very high tumour
uptake in a mouse
model and in
clinical trials.
Significant FR
mediated renal
uptake.

[127,

10-fold less
affinity for FR+ve
KB-31 cells than
folic acid

Low toxicity

In normal Swiss
mice the
conjugate was
effectively
cleared from the
kidneys

[222]

and
[Gd(DOTA)]3+
Tc(V) is complexed
to a peptide (Cys-AspDap-D-Glu-Pte) which
is linked to a folate
moiety via a diamine
group

99m

-O-S-folate constructed
by attaching a cysteinebased (O-S) chelating
group to the γcarboxylate of folic
acid.

[99mTcN(PNP)]2+

Tc-EC20

128,
223225]
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6. CONCLUSION
As it stands, folate-targeted drug therapy is proving to be a rich vein of research into the diagnosis and
treatment of many forms of cancer. This is emphasised by the continuous stream of literature regarding the topic
published since early 2000. However, there is a dearth of published material in relation to studies conducted on folatetargeted metal-based therapies over the same time frame. From the data available, it is apparent that the subject area
is in its infancy and has the potential to contribute greatly to cancer research, both in therapy and diagnosis.
Folic acid is an interesting ligand for metal complex formation, but its coordination chemistry is not well
developed. Incorporating simple folate ligands into biologically active metal complex systems may offer a simple
strategy for improving their selective uptake in FR+ve cells. This remains an avenue yet to be exploited with the issue
of metal complex solubility presenting a significant challenge, as encountered in the work reported thus far. The very
recent introduction of novel FR-selective folate-based coordination complex nanotubes [181, 182], employing very
simple chemistry, and which have excellent anticancer therapeutic potential in their own right, is an exciting example
of this approach. The ability to encapsulate clinical drugs such as cisplatin or doxorubicin in the inner tubes of such
nanotubes further extends the scope to develop selective drug carrier systems with dual therapeutic capability, which
may also lead to new mechanisms of action.
The success of the platinum drugs in treating a range of cancers is compromised by issues relating to toxic
side-effects, drug resistance and the lack of tumour selectivity. Promising recent results show that incorporation of
drugs such as cisplatin and carboplatin into folate- or folate-carrier- systems has the potential to overcome these
problems to some extent by improving their delivery and/or selectivity. Very few non-platinum metal complex
conjugates with folic acid have been reported in the literature, and the majority of studies conducted to date lack
substantial in vitro and/or in vivo data. However, this is an avenue that offers significant potential to develop targeted
therapeutic approaches in areas such as chemotherapy and molecular imaging for diagnostics.
If this approach is to be fully exploited there are experimental challenges to overcome. The synthesis,
purification and characterisation of metal complex-folate (and/or folate-carrier-) conjugates are quite often difficult,
presenting problems in relation to biomedical applications. Furthermore, the expression levels of the folate receptor
in different cell types has been a topic of significant interest with data in the literature being somewhat confusing, a
situation that requires caution when assaying the selectivity of potentially active compounds. For example the breast
cancer cell line MCF-7 has been reported to express normal levels of folate receptor in one study[226], while more
recently it has been reported to overexpress the receptor.[227] Indeed, some authors have even reported the use of the
MCF-7 cell line as negative controls for folate receptor.[226, 228-230] Similarly, in 2012 the folate receptor
expression was reported to be high in the well characterized cervical cancer cell line HeLa,[231] and low in a paper
published in 2013.[232]
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Notwithstanding these challenges, where over-expression of the folate receptor is well documented and a key
cellular feature of diseases such as cancer, inflammation, tuberculosis and parasitic infection, the coupling of the
biologically active inorganic complexes with folate receptor targeted capability is a highly desirable goal, offering the
opportunity to avoid unwanted side-effects during diagnosis and treatment.

LIST OF ABBREVIATIONS
ALL = Acute lymphoblastic leukemia
BMB-CCNT’s = Biomolecule-based coordination complex nanotubes
CLSM = Confocal laser scanning microscopy
DFA = dihydrofolic acid
DHF = Dihydrofolate
DHFR = dihydrofolate reductase
DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
DTPAH3 = diethylenetriaminepentaacetic acid
EEC = endometrioid-type endometrial carcinoma
FA = Folic acid
FITC = Fluorescein isothiocyanate
FR = Folate receptor
FR+ve = Folate receptor positive
FR-ve = Folate receptor negative
FRME = Folate receptor-mediated endocytosis
GPI = glycosylphosphatidylinositol
IP = Intraperitoneal
LLC’s = Luminescent lanthanide complexes
MRI = Magnetic resonance imaging
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MTX = Methotrexate
NADPH = nicotinamide adenine dinucleotide phosphate
NSCLC = Non-small-cell lung cancer
PABA = Para-aminobenzoic acid
PCFT = Proton-coupled folate transporter
PEG = Polyethyleneglycol
PET = positron emission tomography
PFS = Progression-free survival
PDT = photo-dynamic therapy
RFC = Reduced folate carrier
SMDC = Small molecule drug conjugate
SPECT = Single photon emission computed tomography
SWNT = Single-walled carbon nanotube
T-DM1 = Trastuzumab emtansine
THF = Tetrahydrofolate
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